← Back to Home

Prostate cancer combination therapy adds toxicity: 54-patient trial finds no clear added benefit from talazoparib

Can adding a PARP inhibitor earlier in treatment deliver longer disease control? The phase 2 ZZ-FIRST trial did not establish an additional clinical benefit but found more severe adverse events, highlighting the importance of patient selection and long-term safety.

By SURL BioNews

For prostate cancer that has already metastasized, the hope behind intensifying treatment early is to gain time before tumors develop drug resistance. However, the ZZ-FIRST trial, published in Nature Medicine on October 14, offers a cautionary message: among 54 patients with high tumor burden who were not selected by biomarkers, adding talazoparib did not establish a clear additional clinical benefit, while severe adverse events were more common.

This open-label, randomized phase 2 study was conducted at eight centers in Spain. Both groups received androgen deprivation therapy and enzalutamide, with the experimental group also receiving the PARP inhibitor talazoparib. The study aimed to further suppress tumors while the disease remained sensitive to hormone therapy by simultaneously blocking androgen receptor signaling and disrupting DNA repair.

According to trial information from the study sponsor, MEDSIR, the primary endpoint was a confirmed complete prostate-specific antigen (PSA) response. PSA can help track changes after treatment, but a decline in a blood marker represents a different level of evidence from whether patients live longer or their disease progresses later. Assessing whether adding a drug is worthwhile also requires weighing clinical outcomes alongside toxicity.

When MEDSIR announced the ASCO meeting results in June, it reported median radiographic progression-free survival of 45.3 months in the combination group and 31.1 months in the control group. However, that press release did not establish that this difference was statistically significant, and the two medians alone cannot establish superior efficacy. The overall conclusion of the current paper likewise did not establish a clear additional benefit from adding the drug in this population of patients who were not selected by biomarkers.

The safety findings made this trade-off more concrete: grade 3 or higher adverse events occurred in 68% of patients in the combination group, compared with 35% in the control group. There were also two cases of myeloid neoplasms that emerged during treatment in the combination group, with both patients ultimately dying. These events constitute an important safety signal, but “emerging during treatment” does not mean they have been proven to be caused by a single drug; a small trial also makes it difficult to estimate rare risks precisely.

The trial also sought to understand treatment responses through tumor tissue. OncoDaily quoted principal investigator Joaquín Mateo as explaining that the team included tumor biopsies from different time points for spatial transcriptomic analysis to track changes in gene expression during treatment. This type of research may provide clues for future patient selection, but it still requires clinical validation before it can serve as a basis for deciding who should receive the additional drug.

Background

Combinations of PARP inhibitors and androgen receptor inhibitors are being explored at earlier stages of prostate cancer treatment. Disease stage, biomarkers related to DNA repair, and study size are all essential considerations when interpreting different trials. With only 54 participants, ZZ-FIRST is not yet sufficient to rule out potential benefits for specific populations. Its warning is that, before broadly adding the drug, clearer evidence is needed that the additional efficacy is enough to offset the increased harm.

References

  1. Nature Medicine
  2. MEDSIR via PR Newswire
  3. MEDSIR
  4. OncoDaily